Nature CommunicationsER degradation for ER+/HER2– advanced or metastatic breast cancer: a phase 1 trialErika HamiltonRachel M. LaymanDavid CosgroveMichael DansoHui ZhangWei HeSu Young KimJie FanManish R. Patel2025-12-17Full textDOI https://doi.org/10.1038/s41467-025-67485-y